CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug707 Intravenous saline injection (Placebo) Wiki 1.00
drug171 Best Practice Wiki 1.00
drug1402 Tocilizumab Wiki 0.22

Correlated MeSH Terms (7)

Name (Synonyms) Correlation
D007676 Kidney Failure, Chronic NIH 0.58
D003324 Coronary Artery Disease NIH 0.58
D029424 Pulmonary Disease, Chronic Obstructive NIH 0.50
D020521 Stroke NIH 0.45
D008173 Lung Diseases, Obstructive NIH 0.41
D009369 Neoplasms, NIH 0.29
D007239 Infection NIH 0.07

Correlated HPO Terms (5)

Name (Synonyms) Correlation
HP:0001677 Coronary artery atherosclerosis HPO 0.58
HP:0006510 Chronic obstructive pulmonary disease HPO 0.58
HP:0001297 Stroke HPO 0.50
HP:0006536 Obstructive lung disease HPO 0.45
HP:0002664 Neoplasm HPO 0.30

There is one clinical trial.

Clinical Trials

1 Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19：a Single-center, Prospective, Randomised Clinical Trial

This clinical trial is set out to evaluate the safety and efficacy of allogeneic human dental pulp mesenchymal stem cells in the treatment of severe pneumonia caused by COVID-19; to explore the effects of human dental pulp mesenchymal stem cells in the treatment of severe pneumonia of COVID-19 in terms of reducing mortality and improving clinical prognosis; and to discover a new therapeutic strategy for COVID-19 using allogeneic human dental pulp mesenchymal stem cells.

NCT04336254 COVID-19 Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) Other: Intravenous saline injection (Placebo)

Primary Outcomes

Description: Time to Clinical Improvement

Measure: TTCI

Time: 1-28 days

Secondary Outcomes

Description: Lung Lesion by CT

Measure: Lung lesion

Time: 1-28 days

Description: Th1 cytokines: IL-1β, IL- 2, TNF-a, ITN-γ; Th2 cytokines: IL- 4, IL- 6, IL- 10; Immunoglobulins: IgA, IgG, IgM, and total IgE; Lymphocyte counts: CD3+, CD4+, CD8+, CD16+,CD19+, CD56+.

Measure: Immune function

Time: 1-28 days

Description: Time of SARS-CoV-2 test turns negative

Measure: Time of SARS-CoV-2 clearance

Time: 1-28 days

Description: Blood cell count and classification

Measure: Blood test

Time: 1-28 days

Description: Pulse oximetry

Measure: SPO2

Time: 1-28 days

Description: Respiratory rate

Measure: RR

Time: 1-28 days

Description: Body temperature

Measure: Body temperature

Time: 1-28 days

Description: Number of the included patients with hDPSCs-related adverse events, e.g. liver or kidney function failure

Measure: Side effects in the treatment group

Time: 1-28 days

Description: C-reactive protein in microgram per litre

Measure: C-reactive protein (mg/L)

Time: 1-28 days

No related HPO nodes (Using clinical trials)